Aroldis Chapman is gonna be a setup man forever, I guess

29 Comments

Danny Knobler has a column up today asking a question a lot of Reds fans have probably been asking themselves for some time: why in the heck is Aroldis Chapman still the Reds’ setup guy?

He hasn’t allowed a run all year. He has retired 22 of his last 24 hitters. He has a K/BB ratio of 34/5 in 19 and a third innings.  He’s simply dominant. And, given that he was a starter in Cuba and a starter in the Reds minor league system before being put in the pen last year, he should probably be given a chance to start, yes?  No, say the Reds. At least not yet:

“On our team right now, he should stay in the bullpen,” second baseman Brandon Phillips said. “We need someone in the bullpen like him” … [General Manager Walt] Jocketty doesn’t rule out Chapman in the rotation at some point this year, but he also said, “We may become resigned to the fact that he may spend this year in the bullpen.”

Walt: you run the team. How do you become “resigned” to this?  Dusty Baker is in the last year of his contract and you’re his boss.  There’s no way to force that issue here?

Yes, he’s an amazing relief pitcher. But Roy Halladay would be an amazing relief pitcher if you turned him into a setup man. As would every other good starter in baseball. Given that a starter pitches three times as many innings in a season as a setup man, you shouldn’t leave a guy like Chapman in the pen unless and until he shows you he can’t start.

And he can’t show you that until you give him a chance to try.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.